Business Wire

SMOORE

23.9.2021 13:17:15 CEST | Business Wire | Press release

Share
SMOORE Outlines Its Mission of “atomization making life better” at GTNF 2021

SMOORE, a global leader in offering vaping technology solutions, today has made its mark at The Global Tobacco & Nicotine Forum (GTNF) 2021. Senior Vice President of SMOORE and President of FEELM, the flagship atomization tech brand belonging to SMOORE, Frank Han makes the keynote speech to outline SMOORE’s mission of “atomization making life better.”

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210923005511/en/

The Global Tobacco & Nicotine Forum (GTNF) is the world’s leading annual forum discussing the future of the tobacco and nicotine industries. The annual industry conference brings together key stakeholders from around the world, including global tobacco companies, vaping brands, scientists, public health experts, NGOs and policymakers.

In his speech, Frank Han calls upon all stakeholders of the industry to join the mission of “atomization making life better”, promoting the evolution of atomization ecosystem . He asserts that policymakers and NGOs should take the lead in institutional innovations to promote the healthier industry development and more balanced regulations, embracing vaping as a strategy to improve public health while safeguarding against youth vaping. Global media could also involve more people in the unbiased public dialogue on vaping.

Moreover, industry leaders should work together to build up more comprehensive industry standards. As one of the key industry standard setters, SMOORE has developed its vapor and material safety standards, which involve over 300 physical and chemical tests. These standards have also covered all of PMTA tests and the safety evaluation of over 50 atomization materials, thereby guaranteeing industry-leading product quality.

In terms of product innovation , Frank Han indicates that the underlying technology of vaping—atomization, has showed promising prospects in other fields, such as healthcare. With one of its R&D focus on the atomization application in healthcare, SMOORE has made significant progress on the research of atomized medication in the past three years.

“In the near future, more and more people will inhale medicines or vaccines with atomization devices. It could help the world pull through the pandemic,” said Frank Han.

According to Frank Han, SMOORE’s innovations are based on its insights into global consumers’ requirements and the commitment to improving user experience, which is the company’s first principle of product development. Based on the principle, SMOORE launched the world’s first Taste Evaluation Model in 2020, covering 4 dimensions and 51 indexes, so as to establish a scientific system to evaluate vaping tastes.

Moreover, Frank Han points out that scientific innovation is the driving force of the industry’s evolution. Industry pioneers are constantly committed to the cross-disciplinary fundamental research of “atomization science”, to explore the mechanism of atomization.

As the world’s leading atomization tech platform, SMOORE has recruited R&D experts from different backgrounds and built up 7 global research centers around the world. In addition to in-house R&D resources, SMOORE has partnered with top universities to leverage the latest scientific discoveries and transform them into cutting–edge applied technologies.

The industry is also embracing intelligent manufacturing to improve resource efficiency. For example, SMOORE introduced the first fully automated pod production line in the world. Now, a single line of SMOORE can produce 7,200 standard vaporizers per hour.

In partnership with clients, SMOORE has also adopted sustainable practices in all stages of product development, especially manufacturing, so as to fulfill its commitment to reducing carbon footprint.

“Innovation and sustainability are the ideas to which the whole industry has been adhering, since the advent of vaping. The two ideas share a common goal, that is ‘atomization making life better’, which echoes SMOORE’s corporate mission,” said Frank Han.

Committed to the mission of “Atomization making life better”, SMOORE will continue to discover more diversified atomization methods and more advanced technology roadmap while jointly promoting a more inclusive dialogue mechanism along with partners from different sectors.

About SMOORE

SMOORE is a global leader in offering vaping technology solutions, including manufacturing vaping devices, and vaping components, with advanced R&D technology, strong manufacturing capacity, wide-spectrum product portfolio and diverse customer base. The Company is the world's largest vaping device manufacturer in terms of revenue, accounting for 18.9% of the total global market share.

About FEELM

FEELM is a high-end atomization technology brand belonging to SMOORE. Focusing on the research of cutting-edge atomization technology, FEELM also specializes in the development and manufacturing of high quality atomization devices driven by FEELM ceramic coil. “FEELM inside” symbol is on the closed system pods of a number of global leading tobacco companies and vaping companies around the world. The accumulated sales volume of FEELM has surpassed 3 billion pieces per year.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye